A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease

被引:67
作者
Weinstock, M [1 ]
Gorodetsky, E
Poltyrev, T
Gross, A
Sagi, Y
Youdim, M
机构
[1] Hebrew Univ Jerusalem, Sch Med, Dept Pharmacol, IL-91120 Jerusalem, Israel
[2] Techn Fac Med, Dept Pharmacol, Haifa, Israel
[3] IIT, Eve Topf & NPF, Ctr Neurodegenerat Dis, Haifa, Israel
关键词
antidepressant activity; brain-selective MAO inhibition; cholinesterase inhibition; dementia of Alzheimer and Lewy body types; neuroprotection; nigrostriatal dopamine;
D O I
10.1016/S0278-5846(03)00053-8
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Degeneration of cholinergic cortical neurons is one of the main reasons for the cognitive deficit in dementia of the Alzheimer type (AD) and in dementia with Lewy bodies (DLB). Many subjects with AD and DLB have extrapyramidal dysfunction and depression resulting from degeneration of dopaminergic, noradrenergic and serotoninergic neurons. We prepared a novel drug, TV-3326 (N-propargyl-3R-aminoindan-5yl)-ethyl methylcarbamate), with both cholinesterase (ChE) and monoamine oxidase (MAO) inhibitory activity, as potential treatment of AD and DLB. TV-3326 inhibits brain acetyl and butyrylcholinesterase (BuChE) in rats after oral doses of 10-100 mg/kg. After chronic but not acute treatment, it inhibits MAO-A and -B in the brain by more than 70% but has almost no effect on these enzymes in the small intestine in rats and rabbits. The brain selectivity results in minimal potentiation of the pressor response to oral tyramine. TV-3326 acts like other antidepressants in the forced swim test in rats, indicating a potential for antidepressant activity. Chronic treatment of mice with TV-3326 (26 mg/kg) prevents the destruction of nigrostriatal neurons by the neurotoxin MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine). In addition to ChE and MAO inhibition, the propargylamine moiety of TV-3326 confers neuroprotective activity against cytotoxicity induced by ischemia and peroxynitrite in cultured neuronal cells that results from prevention of the fall in mitochondrial membrane potential and antiapoptotic activity. These unique multiple actions of TV-3326 make it a potentially useful drug for the treatment of dementia with Parkinsonian-like symptoms and depression. (C) 2003 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:555 / 561
页数:7
相关论文
共 59 条
[1]   Comparison of extrapyramidal signs in dementia with Lewy bodies and Parkinson's disease [J].
Aarsland, D ;
Ballard, C ;
McKeith, I ;
Perry, RH ;
Larsen, JP .
JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES, 2001, 13 (03) :374-379
[2]   Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment [J].
Arnáiz, E ;
Jelic, V ;
Almkvist, O ;
Wahlund, LO ;
Winblad, B ;
Valind, S ;
Nordberg, A .
NEUROREPORT, 2001, 12 (04) :851-855
[3]   POTENTIATION OF ANTI AKINETIC EFFECT AFTER L-DOPA TREATMENT BY AN INHIBITOR OF MAO-B, DEPRENIL [J].
BIRKMAYER, W ;
RIEDERER, P ;
YOUDIM, MBH ;
LINAUER, W .
JOURNAL OF NEURAL TRANSMISSION, 1975, 36 (3-4) :303-326
[4]  
BIRKMAYER W, 1977, LANCET, V1, P439
[5]  
BORSINI F, 1988, PSYCHOPHARMACOLOGY, V94, P147
[6]   An evaluation of the role of mitochondria in neurodegenerative diseases: mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration [J].
Cassarino, DS ;
Bennett, JP .
BRAIN RESEARCH REVIEWS, 1999, 29 (01) :1-25
[7]  
COLLINS G G S, 1970, Nature (London), V225, P817, DOI 10.1038/225817a0
[8]   ALZHEIMERS-DISEASE - A DISORDER OF CORTICAL CHOLINERGIC INNERVATION [J].
COYLE, JT ;
PRICE, DL ;
DELONG, MR .
SCIENCE, 1983, 219 (4589) :1184-1190
[9]  
Da Prada M, 1988, J Neural Transm Suppl, V26, P31
[10]   EFFECTS OF A SINGLE DOSE OF THE ACETYLCHOLINESTERASE INHIBITOR VELNACRINE ON RECOGNITION MEMORY AND REGIONAL CEREBRAL BLOOD-FLOW IN ALZHEIMERS-DISEASE [J].
EBMEIER, KP ;
HUNTER, R ;
CURRAN, SM ;
DOUGAL, NJ ;
MURRAY, CL ;
WYPER, DJ ;
PATTERSON, J ;
HANSON, MT ;
SIEGFRIED, K ;
GOODWIN, GM .
PSYCHOPHARMACOLOGY, 1992, 108 (1-2) :103-109